Journal: Antimicrobial Agents and Chemotherapy

Article Title: Metabolism, Excretion, and Mass Balance of [ 14 C]-Rezafungin in Animals and Humans

doi: 10.1128/AAC.01390-21

Figure Lengend Snippet: Summary of mean (SD) pharmacokinetic parameters for rezafungin, plasma total radioactivity, and whole blood total radioactivity for human subjects ^a

Article Snippet: For the rat and monkey mass balance study, [ 14 C]-rezafungin (46.53 μCi/mg; radiochemical purity, 99.6%) was synthesized by Moravek (Brea, CA) as a bulk powder, which was compounded with unlabeled rezafungin manufactured by Bachem Americas, Inc. (Torrance, CA) as a solution in a vehicle of 2.5% Tween 80, 5% mannitol, 0.3% glacial acetic acid adjusted to pH 4.5.

Techniques: Clinical Proteomics, Radioactivity

Journal: Antimicrobial Agents and Chemotherapy

Article Title: Metabolism, Excretion, and Mass Balance of [ 14 C]-Rezafungin in Animals and Humans

doi: 10.1128/AAC.01390-21

Figure Lengend Snippet: Scheme of rezafungin metabolism.

Article Snippet: For the rat and monkey mass balance study, [ 14 C]-rezafungin (46.53 μCi/mg; radiochemical purity, 99.6%) was synthesized by Moravek (Brea, CA) as a bulk powder, which was compounded with unlabeled rezafungin manufactured by Bachem Americas, Inc. (Torrance, CA) as a solution in a vehicle of 2.5% Tween 80, 5% mannitol, 0.3% glacial acetic acid adjusted to pH 4.5.

Techniques:

Journal: Antimicrobial Agents and Chemotherapy

Article Title: Metabolism, Excretion, and Mass Balance of [ 14 C]-Rezafungin in Animals and Humans

doi: 10.1128/AAC.01390-21

Figure Lengend Snippet: Mean concentration-time profiles (top: linear; bottom: semi-log) for whole blood/plasma radioactivity and plasma rezafungin for human subjects.

Article Snippet: For the rat and monkey mass balance study, [ 14 C]-rezafungin (46.53 μCi/mg; radiochemical purity, 99.6%) was synthesized by Moravek (Brea, CA) as a bulk powder, which was compounded with unlabeled rezafungin manufactured by Bachem Americas, Inc. (Torrance, CA) as a solution in a vehicle of 2.5% Tween 80, 5% mannitol, 0.3% glacial acetic acid adjusted to pH 4.5.

Techniques: Concentration Assay, Clinical Proteomics, Radioactivity

Journal: Antimicrobial Agents and Chemotherapy

Article Title: Metabolism, Excretion, and Mass Balance of [ 14 C]-Rezafungin in Animals and Humans

doi: 10.1128/AAC.01390-21

Figure Lengend Snippet: Position of radiolabel on [ 14 C]-rezafungin.

Article Snippet: For the rat and monkey mass balance study, [ 14 C]-rezafungin (46.53 μCi/mg; radiochemical purity, 99.6%) was synthesized by Moravek (Brea, CA) as a bulk powder, which was compounded with unlabeled rezafungin manufactured by Bachem Americas, Inc. (Torrance, CA) as a solution in a vehicle of 2.5% Tween 80, 5% mannitol, 0.3% glacial acetic acid adjusted to pH 4.5.

Techniques:

Journal: Antimicrobial Agents and Chemotherapy

Article Title: Candida parapsilosis and echinocandins: should the clinical laboratory drop anidulafungin Etest from the susceptibility testing panel?

doi: 10.1128/aac.00241-25

Figure Lengend Snippet: Echinocandin susceptibility profile of Candida parapsilosis . Heat map illustrating the distribution of minimum inhibitory concentrations (MICs) (µg/mL) of tested echinocandins, including anidulafungin, caspofungin, micafungin, and rezafungin against C. parapsilosis ( n = 60), with data represented by the absolute number of isolates rather than percentages, according to the Clinical and Laboratory Standards Institute (CLSI) ( A ) and Etest ( B ) methods. According to the CLSI breakpoints (M27M44S-Ed3), all echinocandins are categorized as follows: ≤2; susceptible (S), =4; intermediate (I), and ≥8; and resistant (R). An exception is rezafungin, for which the only available categorization is ≤2; susceptible (S). Etest MICs were rounded up to the next higher log2 dilution to facilitate comparison with broth microdilution results.

Article Snippet: Etest strips of anidulafungin (AND; 0.002–32 mg/L; BioMérieux, Vienna, Austria), micafungin (MYC; 0.002–32 mg/L; BioMérieux, Vienna, Austria), caspofungin (CAS; 0.002–32 mg/L; BioMérieux, Vienna, Austria), and rezafungin (RZF; 0.002–32 mg/L; Liofilchem, Roseto degli Abruzzi, TE, Italy) were utilized.

Techniques: Comparison

Journal: Antimicrobial Agents and Chemotherapy

Article Title: Candida parapsilosis and echinocandins: should the clinical laboratory drop anidulafungin Etest from the susceptibility testing panel?

doi: 10.1128/aac.00241-25

Figure Lengend Snippet: Inhibition pattern of a representative clinical Candida parapsilosis isolate (Isolate no. R8) (1), susceptible to anidulafungin (AND) ( A ) by CLSI but resistant by Etest , while susceptible to caspofungin (CS) ( B ), micafungin (MYC) ( C ), and rezafungin (RZF) ( D ) by both methods; (2) C. parapsilosis isolate fks 1 R658G mutant (CP142), classified by CLSI as AND-susceptible, MYC-resistant, and RZF and CS-intermediate, but by Etest showing resistance to AND ( A ) and MYC ( C ), and intermediate to RZF ( D ), and CS ( B ); (3) C. parapsilosis ATCC 22019 and (4) C. krusei ATCC 6258 as quality control strains, both within the accepted CLSI quality control range.

Article Snippet: Etest strips of anidulafungin (AND; 0.002–32 mg/L; BioMérieux, Vienna, Austria), micafungin (MYC; 0.002–32 mg/L; BioMérieux, Vienna, Austria), caspofungin (CAS; 0.002–32 mg/L; BioMérieux, Vienna, Austria), and rezafungin (RZF; 0.002–32 mg/L; Liofilchem, Roseto degli Abruzzi, TE, Italy) were utilized.

Techniques: Inhibition, Mutagenesis, Control